Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

NCT05507606 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Bevacizumab Biosimilar IBI305
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Tianjin Medical University Cancer Institute and Hospital